From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview.